Funding in, findings out
For any dataset: the NCI award that paid to create it, and the awards that got a published finding out of it afterwards.
rectal_msk_2019
Rectal Cancer (MSK,Nature Medicine 2019)
15 awards paid to create it · 0 awards funded work that used it
1. Awards that paid to create this data (6 of 15)
- Modeling metastatic colorectal cancer in vivo · Kevin P. O'Rourke · FY2016–2018
- Investigating L1CAM-dependent stem cell regeneration in metastasis · Karuna Ganesh · FY2018–2022
- MSK Paul Calabresi Career Development Award for Clinical Oncology · Omar Abdel-Wahab, Simon N. Powell · FY2015–2026
- Defining the genetic requirements for maintenance of colorectal cancer · LUKAS Edward DOW · FY2014–2016
- TGF&, PI3K and HER2 Pathways in Breast Cancer Metastasis · JOAN MASSAGUE, SCOTT W. LOWE · FY2002–2018
- Mediators of Lung Adenocarcinoma Metastasis · JOAN MASSAGUE, Piro Lito · FY2026
The best connected are shown.
2. The dataset
3. Articles that used it
4. Awards those articles were funded by
Why one side of this chain is empty
- This dataset has no accession that articles quote, so no reuse can be traced and nothing it enabled is visible.
Awards that paid to create this data
Credited on the dataset's own marker paper.
| Award | Project | Evidence |
|---|---|---|
| F30CA200110 F30FY2016–2018$138k | Modeling metastatic colorectal cancer in vivo | API |
| K08CA230213 K08FY2018–2022$1.3M | Investigating L1CAM-dependent stem cell regeneration in metastasis | API |
| K12CA184746 K12FY2015–2026$8.3M | MSK Paul Calabresi Career Development Award for Clinical Oncology | API |
| K22CA181280 K22FY2014–2016$584k | Defining the genetic requirements for maintenance of colorectal cancer | API |
| P01CA094060 P01FY2002–2018$67.2M | TGF&, PI3K and HER2 Pathways in Breast Cancer Metastasis | API |
| P01CA129243 P01FY2026$4.9M | Mediators of Lung Adenocarcinoma Metastasis | API |
| P30CA008748 P30FY2025–2026$48.4M | Antitumor Assessment | API |
| P50CA092629 P50FY2025–2026$5.2M | SPORE in Prostate Cancer | API |
| R01CA155169 R01FY2012–2022$3.8M | Understanding Resistance to Next Generation Antiandrogens | API |
| R01CA182551 R01FY2014–2018$3.1M | Organ Preservation in Rectal Adenocarcinoma | API |
| R01CA193837 R01FY2015–2025$4.7M | Role of ETS factors in specifying prostate luminal cell identity and androgen receptor dependence | API |
| R25CA020449 R25FY1985–2026$7.0M | Summer research experiences for medical students supervised by faculty mentors | API |
| T32CA009207 T32FY1985–2026$20.1M | Investigational Cancer Therapeutics Training Program (ICTTP) | API |
| T32CA160001 T32FY2011–2020$2.0M | Translational Research in Oncology Training Program | API |
| U54CA224079 U54FY2017–2021$13.6M | Project 2: Reversing resistance caused by lineage plasticity through epigenetic therapy | API |
Where the links come from
NIH RePORTER maps a PMID to the awards that reported it. On a dataset’s marker paper that gives the awards which created it; on an article that used the data, the awards which funded that use.
The two sides are not measured alike. Generation is complete: a dataset has one marker paper and every award on it is resolved. Reuse is a sample - the articles using a dataset can number in the thousands, and only the few dozen strongest are retrieved and looked up. Every award shown here funded reuse; there are more that are not shown.
How far it reaches
283 datasets have an award credited with creating them, 80 with using them, and 31 both.
What is missing
No citable accession means no traceable articles; no authoritative marker paper means no attributable generation award. Absence is a gap in the record. Methods.
Start from an award instead, and see every dataset it touches.